Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

geron - GERN

GERN

Close Chg Chg %
1.37 0.00 0.00%

Closed Market

1.37

0.00 (0.00%)

Volume: 8.78M

Last Updated:

Jan 8, 2026, 4:00 PM EDT

Trade Now

Company Overview: geron - GERN

GERN Key Data

Open

$1.35

 Day Range

1.32 - 1.40

52 Week Range

1.04 - 3.45

 Market Cap

$842.63M

Shares Outstanding

638.36M

 Public Float

607.35M

Beta

0.59

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.12

Yield

0.00%

 Dividend

$0.15

EX-DIVIDEND DATE

Jul 22, 2014

 SHORT INTEREST

N/A

AVERAGE VOLUME

6.51M

  

GERN Performance

1 Week
 
 3.79%
 
1 Month
 
 0.74%
 
3 Months
 
 4.58%
 
1 Year
 
 -56.78%
 
5 Years
 
 -19.88%
 

GERN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About geron - GERN

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

GERN At a Glance

Geron Corp.
919 East Hillsdale Boulevard
Foster City, California 94404
Phone 1-650-473-7700 Revenue 76.99M
Industry Biotechnology Net Income -174,572,000.00
Sector Health Technology 2024 Sales Growth 32,386.92%
Fiscal Year-end 12 / 2025 Employees 229
View SEC Filings

GERN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 29.703
Price to Book Ratio 7.658
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -12.318
Enterprise Value to Sales 27.60
Total Debt to Enterprise Value 0.116

GERN Efficiency

Revenue/Employee 336,218.341
Income Per Employee -762,323.144
Receivables Turnover 1.984
Total Asset Turnover 0.156

GERN Liquidity

Current Ratio 5.561
Quick Ratio 5.122
Cash Ratio 4.626

GERN Profitability

Gross Margin 98.369
Operating Margin -225.644
Pretax Margin -226.735
Net Margin -226.735
Return on Assets -35.319
Return on Equity -66.092
Return on Total Capital -33.136
Return on Invested Capital -44.112

GERN Capital Structure

Total Debt to Total Equity 87.938
Total Debt to Total Capital 46.791
Total Debt to Total Assets 41.468
Long-Term Debt to Equity 80.324
Long-Term Debt to Total Capital 42.739
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Geron - GERN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.39M 596.00K 237.00K 76.99M
Sales Growth
+450.59% -57.21% -60.23% +32,386.92%
Cost of Goods Sold (COGS) incl D&A
783.00K 868.00K 1.03M 1.26M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
783.00K 868.00K 1.03M 1.22M
Depreciation
783.00K 868.00K 1.03M 1.22M
Amortization of Intangibles
- - - -
-
COGS Growth
- +10.86% +19.01% +21.59%
Gross Income
610.00K (272.00K) (796.00K) 75.74M
Gross Income Growth
- -144.59% -192.65% +9,614.82%
Gross Profit Margin
+43.79% -45.64% -335.86% +98.37%
2021 2022 2023 2024 5-year trend
SG&A Expense
114.61M 138.28M 193.15M 249.47M
Research & Development
85.73M 95.52M 125.05M 103.74M
Other SG&A
28.88M 42.76M 68.10M 145.73M
SGA Growth
+50.34% +20.65% +39.68% +29.16%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.71M
-
EBIT after Unusual Expense
(114.00M) (138.55M) (193.94M) (175.44M)
Non Operating Income/Expense
1.63M 3.53M 18.13M 19.37M
Non-Operating Interest Income
527.00K 2.53M 18.15M 19.61M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.74M 6.88M 8.31M 18.50M
Interest Expense Growth
+392.11% +84.01% +20.78% +122.62%
Gross Interest Expense
3.74M 6.88M 8.31M 18.50M
Interest Capitalized
- - - -
-
Pretax Income
(116.11M) (141.90M) (184.13M) (174.57M)
Pretax Income Growth
-53.55% -22.21% -29.76% +5.19%
Pretax Margin
-8,335.39% -23,808.89% -77,690.72% -226.73%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(116.11M) (141.90M) (184.13M) (174.57M)
Minority Interest Expense
- - - -
-
Net Income
(116.11M) (141.90M) (184.13M) (174.57M)
Net Income Growth
-53.55% -22.21% -29.76% +5.19%
Net Margin Growth
-8,335.39% -23,808.89% -77,690.72% -226.73%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(116.11M) (141.90M) (184.13M) (174.57M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(116.11M) (141.90M) (184.13M) (174.57M)
EPS (Basic)
-0.3544 -0.3726 -0.3227 -0.2702
EPS (Basic) Growth
-27.21% -5.14% +13.39% +16.27%
Basic Shares Outstanding
327.63M 380.78M 570.65M 646.03M
EPS (Diluted)
-0.3544 -0.3726 -0.3227 -0.2702
EPS (Diluted) Growth
-27.21% -5.14% +13.39% +16.27%
Diluted Shares Outstanding
327.63M 380.78M 570.65M 646.03M
EBITDA
(113.22M) (137.68M) (192.91M) (172.51M)
EBITDA Growth
-49.01% -21.61% -40.11% +10.57%
EBITDA Margin
-8,127.49% -23,101.01% -81,397.05% -224.06%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 3.333
Number of Ratings 6 Current Quarters Estimate -0.031
FY Report Date 03 / 2026 Current Year's Estimate -0.043
Last Quarter’s Earnings -0.025 Median PE on CY Estimate N/A
Year Ago Earnings -0.105 Next Fiscal Year Estimate 0.044
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 6 5
Mean Estimate -0.03 -0.02 -0.04 0.04
High Estimates -0.02 0.00 0.03 0.19
Low Estimate -0.04 -0.04 -0.16 -0.10
Coefficient of Variance -23.95 -80.80 -147.16 233.77

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 5
OVERWEIGHT 0 0 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Geron - GERN

Date Name Shares Transaction Value
Jan 7, 2026 Robert Jay Spiegel Director 194,464 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.32 per share 256,692.48
Mar 3, 2025 John A. Scarlett Chairman, President and CEO; Director 12,500 Open market or private purchase of non-derivative security Non-derivative transaction at $1.76 per share 22,000.00
Mar 3, 2025 Scott Alan Samuels EVP, Chief Legal Officer 26,682 Open market or private purchase of non-derivative security Non-derivative transaction at $1.61 per share 42,958.02
Mar 3, 2025 Jim Ziegler EVP, Chief Commercial Officer 100,000 Open market or private purchase of non-derivative security Non-derivative transaction at $1.6 per share 160,000.00
Feb 21, 2025 Andrew J. Grethlein EVP, Chief Operating Officer 839,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Andrew J. Grethlein EVP, Chief Operating Officer 140,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 John A. Scarlett Chairman, President and CEO; Director 410,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Scott Alan Samuels EVP, Chief Legal Officer 104,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Jim Ziegler EVP, Chief Commercial Officer 89,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Michelle Robertson EVP, Chief Financial Officer 656,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Michelle Robertson EVP, Chief Financial Officer 110,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Geron in the News